Viridian Therapeutics Inc...

NASDAQ: VRDN · Real-Time Price · USD
18.23
-0.21 (-1.14%)
At close: Aug 15, 2025, 2:33 PM

Viridian Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
302K 314K 1.77M 2.96M
Cost of Revenue
n/a 1.32M 755K 620K
Gross Profit
302K -1.01M 1.02M 2.34M
Operating Income
-299.04M -254.45M -134.3M -79.73M
Interest Income
32.13M 18.56M 4.92M 318K
Pretax Income
-269.95M -237.73M -129.87M -79.41M
Net Income
-269.95M -237.73M -125.44M -79.42M
Selling & General & Admin
61.08M 95M 35.18M 25.8M
Research & Development
238.25M 159.76M 100.89M 56.89M
Other Expenses
n/a n/a n/a n/a
Operating Expenses
299.34M 254.76M 136.08M 82.69M
Interest Expense
3.05M 1.85M 486K 3K
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
299.34M 254.76M 136.08M 82.69M
Income Tax Expense
n/a n/a -4.43M 3K
Shares Outstanding (Basic)
67.89M 44.76M 32.09M 11.92M
Shares Outstanding (Diluted)
67.89M 44.76M 32.09M 11.92M
EPS (Basic)
-3.98 -5.31 -3.91 -6.66
EPS (Diluted)
-3.98 -5.31 -3.91 -6.66
EBITDA
-265.66M -234.56M -128.63M -78.79M
EBIT
-266.9M -235.89M -129.39M -79.41M
Depreciation & Amortization
1.24M 522K 755K 620K